Clinical markers of long-term disability in RRMS patients treated with interferon beta

被引：0
|
作者：
Rio, J. [1 ]
Otero-Romero, S. [1 ,2 ]
Tintore, M. [1 ]
Comabella, M. [1 ]
Nos, C. [1 ]
Negrotto, L. [1 ]
Galan, I. [1 ]
Vidal-Jordana, A. [1 ]
Castillo, J. [1 ]
Palavra, F. [1 ]
Simon, E. [1 ]
Arrambide, G. [1 ]
Sastre-Garriga, J. [1 ]
Montalban, X. [1 ]
机构：
[1] Vall Hebron Univ Hosp, Multiple Sclerosis Ctr Catalonia, Dept Neuroimmunol, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Prevent Med & Epidemiol Dept, Barcelona, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P285
引用
收藏
页码：194 / 194
页数：1
相关论文
共 50 条
  • [41] Early Clinical Predictors of Long-term Disability Progression in Patients with Multiple Sclerosis
    Ignatova, Valentina Georgieva
    Todorova, Lyudmila Pavlova
    Haralanov, Lyubomir Haralanov
    Vassilev, Peter M.
    INDIAN JOURNAL OF MEDICAL SPECIALITIES, 2024, 15 (01) : 48 - 52
  • [42] Can we predict which CML patients treated with interferon will be long-term survivors?
    Murro, HH
    Bezares, RF
    Caviglia, D
    Saidón, G
    Díaz, A
    BLOOD, 1999, 94 (10) : 277B - 277B
  • [43] Evidence for Long-Term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials
    Foley, John F.
    Zerkowski, Kristine
    Nair, Kavita V.
    JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (01): : S4 - S15
  • [44] Long-term clinical assessment in patients with Eisenmenger Syndrome treated with macitentan
    Zebadua, R.
    Lopez, J. C.
    Zayas, N. G.
    Sandoval, J.
    Villalobos-Pedroza, M.
    Cruz, A.
    Hernandez, D. K.
    Canul, F.
    Pulido, T.
    Hdz, N. G. Zayas
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [45] Long-term outcome of chronic hepatitis C treated with interferon
    Hadziyannis, SJ
    Papatheodoridis, GV
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (06): : 459 - 461
  • [46] Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis
    Coppola, G.
    Lanzillo, R.
    Florio, C.
    Orefice, G.
    Vivo, P.
    Ascione, S.
    Schiavone, V.
    Pagano, A.
    Vacca, G.
    De Michele, G.
    Morra, V. Brescia
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (09) : 1014 - 1021
  • [47] Long-term Outcome of Schilder Disease Treated With Interferon-β
    Lin, Wei-Sheng
    Kuo, Meng-Fai
    Peng, Steven Shinn-Forng
    Fan, Pi-Chuan
    PEDIATRICS, 2019, 144 (05)
  • [48] Long-term effect of natalizumab in a French cohort of patients with RRMS: TYSTEN cohort
    Bigaut, K.
    Fabacher, T.
    Collongues, N.
    Kremer, L.
    Fleury, M. -C.
    Ongagna, J. -C.
    De Seze, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 918 - 918
  • [49] Clinical Markers of Therapeutic Response & the Long-Term Impact of Glatiramer Acetate on Relapse-Induced Disability
    Carra, Adriana J.
    Onaha, Patricia S.
    Rojas, Galeno
    Imhoff-Jullier, Gaston
    Vrech, Carlos
    NEUROLOGY, 2010, 74 (09) : A156 - A157
  • [50] Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial
    Kappos, Ludwig
    Edan, Gilles
    Freedman, Mark S.
    Hartung, Hans-Peter
    Montalban, Xavier
    Barkhof, Frederik
    Koelbach, Ralf
    MacManus, David G.
    Wicklein, Eva-Maria
    JOURNAL OF NEUROLOGY, 2024, 271 (07) : 4599 - 4609
12345